| Date Filed | Type | Description |
| 09/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/21/2023 |
4
| Burns James William (Chief Legal Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 6,395 shares
@ $26.28, valued at
$168.1k
|
|
| 08/15/2023 |
4
| Ballal Rahul D. (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Exercised 2,302 restricted stock units
@ $0 |
|
| 08/15/2023 |
4
| Smith Cynthia (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Exercised 2,302 restricted stock units
@ $0 |
|
| 08/11/2023 |
4
| Foster-Cheek Kaye I (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 25,000 shares
@ $25.9555, valued at
$648.9k
Exercised 25,000 options to buy
@ $18.09, valued at
$452.3k
|
|
| 08/10/2023 |
4
| Goff Brian (CEO) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 10,178 shares
@ $25.48, valued at
$259.3k
Exercised 22,691 restricted stock units
@ $0 |
|
| 08/09/2023 |
4
| Washburn Theodore James Jr. (Principal Accounting Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 2,918 shares
@ $25.3927, valued at
$74.1k
|
|
| 08/02/2023 |
4
| Washburn Theodore James Jr. (Principal Accounting Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 1,232 shares
@ $26.26, valued at
$32.4k
Exercised 4,150 restricted stock units
@ $0 |
|
| 07/06/2023 |
4
| Gheuens Sarah (Chief Medical Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Granted 25,124 restricted stock units
@ $0 |
|
| 06/30/2023 |
4
| Burns James William (Chief Legal Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 1,707 shares
@ $28.36, valued at
$48.4k
Exercised 5,750 options to buy
@ $0 |
|
| 06/30/2023 |
4
| FOUSE JACQUALYN A (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 10,718 shares
@ $28.36, valued at
$304k
Exercised 23,900 options to buy
@ $0 |
|
| 06/30/2023 |
4
| Gheuens Sarah (Chief Medical Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 1,707 shares
@ $28.36, valued at
$48.4k
Exercised 5,750 options to buy
@ $0 |
|
| 06/30/2023 |
4
| Goff Brian (CEO) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 11,449 shares
@ $28.36, valued at
$324.7k
Exercised 25,528 options to buy
@ $0 |
|
| 06/30/2023 |
4
| Jones Cecilia (CFO) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 1,597 shares
@ $28.36, valued at
$45.3k
Exercised 5,380 options to buy
@ $0 |
|
| 06/30/2023 |
4
| Milanova Tsveta (Chief Commercial Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 1,618 shares
@ $28.36, valued at
$45.9k
Exercised 5,449 options to buy
@ $0 |
|
| 04/05/2023 |
4
| Schenkein David P (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 16,363 shares
@ $22.85, valued at
$373.9k
Exercised 16,363 options to buy
@ $9.05, valued at
$148.1k
|
|
| 03/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/15/2023 |
4
| Schenkein David P (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 18,333 shares
@ $22.47, valued at
$411.9k
Sold 1,667 shares
@ $22.72, valued at
$37.9k
Exercised 20,000 options to buy
@ $9.05, valued at
$181k
|
|
| 03/07/2023 |
4
| Washburn Theodore James Jr. (Principal Accounting Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 504 shares
@ $24.29, valued at
$12.2k
|
|
| 03/01/2023 |
4
| Schenkein David P (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 20,000 shares
@ $25.37, valued at
$507.4k
Exercised 20,000 options to buy
@ $9.05, valued at
$181k
|
|
| 02/14/2023 |
4
| Burns James William (Chief Legal Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 643 shares
@ $28.44, valued at
$18.3k
Exercised 1,834 restricted stock units
@ $0 |
|
| 02/14/2023 |
4
| Washburn Theodore James Jr. (Principal Accounting Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 273 shares
@ $28.44, valued at
$7.8k
Granted 6,896 restricted stock units
@ $0
Exercised 777 restricted stock units
@ $0 |
|
| 02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/19/2023 |
4
| Schenkein David P (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 18,966 shares
@ $28.82, valued at
$546.6k
Sold 1,034 shares
@ $29.49, valued at
$30.5k
Exercised 20,000 options to buy
@ $9.05, valued at
$181k
|
|
| 01/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/05/2023 |
4
| Milanova Tsveta (Chief Commercial Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Granted 135,682 options to buy
@ $27.53, valued at
$3.7M
Granted 25,426 restricted stock units
@ $0 |
|
| 01/05/2023 |
3
| Milanova Tsveta (Chief Commercial Officer) has filed a Form 3 on AGIOS PHARMACEUTICALS, INC. |
| 12/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/18/2022 |
4
| Poddar Richa (Chief Commercial Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 1,485 shares
@ $27.48, valued at
$40.8k
Exercised 5,000 restricted stock units
@ $0 |
|
| 09/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/28/2022 |
3
| Jones Cecilia (CFO) has filed a Form 3 on AGIOS PHARMACEUTICALS, INC. |
| 08/15/2022 |
4
| Smith Cynthia (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Granted 37,947 options to buy
@ $25.99, valued at
$986.2k
Granted 6,906 restricted stock units
@ $0 |
|
|